MannKind resubmits NDA for diabetes drug Afrezza after positive study results

14 October 2013

US drugmaker MannKind (Nasdaq: MNKD) has resubmitted its New Drug Application to the US Food and Drug Administration for the marketing and sale of Afrezza (insulin human [rDNA origin]) Inhalation Powder for adults with type 1 or type 2 diabetes.

In 2011, the FDA issued a complete response letter in which it raised concerns that the usage of in vitro performance data and clinical pharmacology data to bridge MannKind's next-generation inhaler to the Phase III trials conducted using its MedTone inhaler. It requested that MannKind conduct two clinical trials with the next-generation inhaler (one in patients with type 1 diabetes and one in those with type 2 disease).

Entire new data set resubmitted

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK